We are live on ! Find out more
EIDX

Eidos Therapeutics
EIDX

Delisted

EIDX was delisted on the 25th of January, 2021.

0 hedge funds and large institutions have $0 invested in Eidos Therapeutics in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 120 closing their positions.

New
Increased
Maintained
Reduced
Closed

28.93% less ownership

Funds ownership: 28.93% → 0% (-29%)

100% less funds holding

Funds holding: 121 → 0 (-121)

100% less funds holding in top 10

Funds holding in top 10: 6 → 0 (-6)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $1.48B

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 120

Holders
–
Holders Change
-121
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-6
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
120
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

EIDX Hedge Fund Activity: Q1 2021 in Review

0 of the 5,715 institutional investors tracked by Wall St. Rank reported a position in Eidos Therapeutics (EIDX) for Q1 2021, worth a combined $0 — down 100% from $1.48B a quarter earlier.

Sellers outnumbered buyers: 120 funds closed out of EIDX and 0 opened new positions — a net loss of 120 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $205M sold.

  • 0 institutional investors held Eidos Therapeutics (EIDX) as of Q1 2021, down from 121 in Q4 2020.
  • Funds reported $0 of Eidos Therapeutics stock for Q1 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Eidos Therapeutics positions in Q1 2021 and 120 closed out, a net change of -120 holders.
  • The largest Eidos Therapeutics seller in Q1 2021 was BlackRock, an estimated $205M sold.

Based on aggregated 13F filings for Q1 2021.